Drug intelligence / Profile preview

radgocitabine

Development stage: Phase 3
Lead developer: Delta-Fly Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

Radgocitabine (also known as TAS-109 or CNDAC) is a small molecule deoxycytidine analogue developed by Taiho Pharmaceutical for the treatment of advanced colorectal cancer. As a nucleoside analog, it acts as a DNA synthesis inhibitor by incorporating into the DNA of cancer cells, leading to DNA strand breaks and interference with DNA function. It has been evaluated in Phase II clinical trials specifically for patients with chemotherapy-refractory metastatic colorectal cancer, where it is typically administered as a 14-day continuous intravenous infusion to maintain therapeutic levels.

Other names: radgocitabine

Targets

DNA polymerase familyDNA

Beyond the preview

Go deeper on radgocitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on radgocitabine.

Explore the full profile